(Q38212848)

English

Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis

scientific article published on 20 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

0 references

Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

bone scintigraphy

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Guohua Shen

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Houfu Deng

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Shuang Hu

3

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Zhiyun Jia

4

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Skeletal Radiology

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

1503-1513

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

https://scigraph.springernature.com/pub.10.1007/s00256-014-1903-9

0 references

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Conventional treatments of localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Radionuclide bone imaging: an illustrative review

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Usefulness of single photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Prostate cancer: role of SPECT and PET in imaging bone metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Positron emission tomography and bone metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Baseline staging of newly diagnosed prostate cancer: a summary of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Bone marrow imaging

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Molecular imaging of prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT.

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

Does Magnetic Resonance Imaging of the Spine Have a Role in the Staging of Prostate Cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS00256-014-1903-9

21 January 2018

A definition of molecular imaging.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of positron emission tomography in the management of bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distribution of bony metastases in prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?--a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of bone SPET study in diagnosis of single vertebral metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00256-014-1903-9

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38212848&oldid=1747411637"